Evidence map›Paper›PMID 33935791›Full record

ArticleFrontiers in pharmacology2021

Generation and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release.

Jonathan Shpigelman, Fitzgerald S Lao, Shiyin Yao, Chenyang Li, Tetsuya Saito, Fumi Sato-Kaneko, John P Nolan, Nikunj M Shukla, Minya Pu, Karen Messer and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Rigor and reproducibility: status and challenges for single vesicle analysis.Extracellular vesicles and circulating nucleic acids · 2022
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Jonathan ShpigelmanMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Fitzgerald S LaoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Shiyin YaoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Chenyang LiSchool of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.
Tetsuya SaitoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Fumi Sato-KanekoMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
John P NolanScintillon Institute, San Diego, CA, United States.
Nikunj M ShuklaMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Minya PuMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Karen MesserMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Howard B CottamMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Dennis A CarsonMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Maripat CorrDepartment of Medicine, University of California, San Diego, La Jolla, CA, United States.
Tomoko HayashiMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
University of California, San Diego · USScintillon Institute · USShenzhen University Health Science Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are identified as mediators of intercellular communication and cellular regulation. In the immune system, EVs play a role in antigen presentation as a part of cellular communication. To enable drug discovery and characterization of compounds that affect EV biogenesis, function, and release in immune cells, we developed and characterized a reporter cell line that allows the quantitation of EVs shed into culture media in phenotypic high-throughput screen (HTS) format. Tetraspanins CD63 and CD9 were previously reported to be enriched in EVs; hence, a construct with dual reporters consisting of CD63-Turbo-luciferase (Tluc) and CD9-Emerald green fluorescent protein (EmGFP) was engineered. This construct was transduced into the human monocytic leukemia cell line, THP-1. Cells expressing the highest EmGFP were sorted by flow cytometry as single cell, and clonal pools were expanded under antibiotic selection pressure. After four passages, the green fluorescence dimmed, and EV biogenesis was then tracked by luciferase activity in culture supernatants. The Tluc activities of EVs shed from CD63Tluc-CD9EmGFP reporter cells in the culture supernatant positively correlated with the concentrations of released EVs measured by nanoparticle tracking analysis. To examine the potential for use in HTS, we first miniaturized the assay into a robotic 384-well plate format. A 2210 commercial compound library (Maybridge) was then screened twice on separate days, for the induction of extracellular luciferase activity. The screening data showed high reproducibility on days 1 and 2 (78.6%), a wide signal window, and an excellent Z' factor (average of 2-day screen, 0.54). One hundred eighty-seven compounds showed a response ratio that was 3SD above the negative controls in both day 1 and 2 screens and were considered as hit candidates (approximately 10%). Twenty-two out of 40 re-tested compounds were validated. These results indicate that the performance of CD63Tluc-CD9EmGFP reporter cells is reliable, reproducible, robust, and feasible for HTS of compounds that regulate EV release by the immune cells.

Indexed as

antigen-presenting cellsCD63CD9exosomeextracellular vesicleluciferaseTHP-1

Identifiers

PMID33935791
PMCPMC8085554
OpenAlexW3153898429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.